Department of Nuclear Medicine, The First Affiliated Hospital of Naval Medical University.
Department of Nuclear Medicine, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, China.
Nucl Med Commun. 2023 Sep 1;44(9):767-771. doi: 10.1097/MNM.0000000000001725. Epub 2023 Jul 3.
To assess the added value of 99m Tc-MIBI single-photon emission computed tomography/computed tomography (SPECT/CT) fusion imaging over dual-phase scintigraphy in the diagnosis of secondary hyperparathyroidism (SHPT).
This retrospective study included 23 patients with SHPT. The diagnostic efficacy of 99m Tc-MIBI dual-phase scintigraphy and SPECT/CT fusion imaging was analyzed and compared based on the result of postoperative pathology and follow-up. To evaluate the diagnostic ability of 99m Tc-MIBI dual-phase scintigraphy, the volume and radioactive count of parathyroid lesions were assessed using the region of interest method.
A total of 79 hyperplastic parathyroid glands and two thyroid tissues were surgically removed from 23 SHPT patients and 13 normal parathyroid glands were preserved. 99m Tc-MIBI SPECT/CT fusion imaging showed higher sensitivity and accuracy than 99m Tc-MIBI dual-phase scintigraphy [sensitivity, 77.2% (61/79) vs 46.8% (37/79); accuracy, 80.4% (74/92) vs 54.3% (50/92), respectively], but comparable specificity [100% (13/13)). Among 61 positive lesions detected by 99m Tc-MIBI SPECT/CT fusion imaging, 37 were dual-phase scintigraphy positive and 24 were dual-phase scintigraphy false negative. The radioactivity counts and radioactivity per unit volume in dual-phase scintigraphy positive were higher than that in dual-phase scintigraphy false negative ( P < 0.05), but the volume of parathyroid lesions between the two groups had no significant difference ( P > 0.05).
Compared with 99m Tc-MIBI dual-phase scintigraphy, 99m Tc-MIBI SPECT/CT fusion imaging has incremental value in the diagnosis of SHPT. The low uptake of MIBI in the whole gland and low MIBI uptake per unit volume are easy to cause dual-phase scintigraphy false negative.
评估 99mTc-MIBI 单光子发射计算机断层扫描/计算机断层扫描(SPECT/CT)融合显像在诊断继发性甲状旁腺功能亢进(SHPT)中的附加价值。
本回顾性研究纳入了 23 例 SHPT 患者。基于术后病理和随访结果,分析并比较了 99mTc-MIBI 双时相闪烁显像和 SPECT/CT 融合显像的诊断效能。采用感兴趣区(ROI)法评估甲状旁腺病变的体积和放射性计数,以评估 99mTc-MIBI 双时相闪烁显像的诊断效能。
23 例 SHPT 患者共手术切除 79 个增生性甲状旁腺和 2 个甲状腺组织,保留 13 个正常甲状旁腺。99mTc-MIBI SPECT/CT 融合显像的敏感性和准确性均高于 99mTc-MIBI 双时相闪烁显像[敏感性分别为 77.2%(61/79)和 46.8%(37/79);准确性分别为 80.4%(74/92)和 54.3%(50/92)],但特异性相当[均为 100%(13/13)]。在 99mTc-MIBI SPECT/CT 融合显像阳性的 61 个病变中,有 37 个为双时相闪烁显像阳性,24 个为双时相闪烁显像假阴性。双时相闪烁显像阳性的放射性计数和放射性计数/单位体积均高于双时相闪烁显像假阴性(P<0.05),但两组甲状旁腺病变体积无显著差异(P>0.05)。
与 99mTc-MIBI 双时相闪烁显像相比,99mTc-MIBI SPECT/CT 融合显像在诊断 SHPT 方面具有附加价值。整个腺体对 MIBI 的摄取低以及单位体积的摄取低,容易导致双时相闪烁显像假阴性。